Latest Insider Transactions at Intra Cellular Therapies, Inc. (ITCI)
This section provides a real-time view of insider transactions for Intra Cellular Therapies, Inc. (ITCI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intra-Cellular Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intra-Cellular Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
34,396
-1.56%
|
$2,510,908
$73.03 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,396
+3.02%
|
$412,752
$12.73 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
35,604
-1.62%
|
$2,563,488
$72.85 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,604
+3.12%
|
$427,248
$12.73 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
32,699
-1.48%
|
$2,387,027
$73.22 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,699
+2.88%
|
$555,883
$17.57 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,513
-1.84%
|
$2,957,449
$73.63 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,513
+3.52%
|
$688,721
$17.57 P/Share
|
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,713
-2.08%
|
$1,680,762
$74.59 P/Share
|
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,713
+2.04%
|
$386,121
$17.57 P/Share
|
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
28,680
-2.61%
|
$2,122,320
$74.46 P/Share
|
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,680
+2.54%
|
$487,560
$17.57 P/Share
|
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
39,380
-1.78%
|
$2,953,500
$75.03 P/Share
|
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,380
+3.43%
|
$669,460
$17.57 P/Share
|
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
53,013
-1.19%
|
$4,028,988
$76.7 P/Share
|
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,013
+4.51%
|
$901,221
$17.57 P/Share
|
|
Aug 16
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,714
-38.65%
|
$1,403,550
$75.08 P/Share
|
|
Aug 16
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,714
+27.88%
|
$673,704
$36.89 P/Share
|
|
Jun 28
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
262
+0.22%
|
$17,816
$68.49 P/Share
|
|
Jun 28
2024
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
83
+0.73%
|
$5,644
$68.49 P/Share
|
|
Jun 24
2024
|
Rory B Riggs |
SELL
Open market or private sale
|
Direct |
4,462
-3.69%
|
$334,650
$75.57 P/Share
|
|
Jun 24
2024
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+14.18%
|
$320,000
$16.86 P/Share
|
|
Jun 23
2024
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,567
+1.53%
|
-
|
|
Jun 23
2024
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
1,567
+3.66%
|
-
|
|
Jun 23
2024
|
Eduardo Rene Salas |
BUY
Exercise of conversion of derivative security
|
Direct |
1,567
+50.0%
|
-
|
|
Jun 23
2024
|
Robert L Van Nostrand |
BUY
Exercise of conversion of derivative security
|
Direct |
1,567
+12.22%
|
-
|
|
Jun 18
2024
|
Robert L Van Nostrand |
SELL
Open market or private sale
|
Direct |
20,000
-41.68%
|
$1,500,000
$75.89 P/Share
|
|
Jun 18
2024
|
Robert L Van Nostrand |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+40.25%
|
$320,000
$16.86 P/Share
|
|
Apr 24
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,020
+0.93%
|
$340,340
$17.22 P/Share
|
|
Mar 31
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
260
+0.26%
|
$17,940
$69.2 P/Share
|
|
Mar 31
2024
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
79
+0.81%
|
$5,451
$69.2 P/Share
|
|
Mar 20
2024
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.77%
|
$360,000
$18.56 P/Share
|
|
Mar 11
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,712
-5.53%
|
$241,280
$65.97 P/Share
|
|
Mar 11
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,345
-7.04%
|
$477,425
$65.96 P/Share
|
|
Mar 11
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,345
-91.57%
|
$484,770
$66.26 P/Share
|
|
Mar 11
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
10,121
-95.16%
|
$667,986
$66.55 P/Share
|
|
Mar 11
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
20,565
-0.48%
|
$1,357,290
$66.21 P/Share
|
|
Mar 10
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+23.8%
|
-
|
|
Mar 10
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+16.55%
|
-
|
|
Mar 10
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+50.0%
|
-
|
|
Mar 10
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,121
+50.0%
|
$566,776
$56.73 P/Share
|
|
Mar 10
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,565
+1.88%
|
-
|
|
Mar 07
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,450
-15.44%
|
$425,700
$66.6 P/Share
|
|
Mar 07
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,132
-16.66%
|
$866,712
$66.66 P/Share
|
|
Mar 07
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
13,132
-99.16%
|
$866,712
$66.47 P/Share
|
|
Mar 07
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
13,132
-74.8%
|
$866,712
$66.6 P/Share
|
|
Mar 07
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,712
-1.88%
|
$2,686,992
$66.65 P/Share
|
|
Mar 06
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+36.73%
|
-
|
|
Mar 06
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+50.0%
|
-
|
|
Mar 06
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+50.0%
|
-
|